You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: May 17, 2024

Claims for Patent: 11,439,598

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 11,439,598

Title:	Synthetic progestogens and pharmaceutical compositions comprising the same
Abstract:	Described herein are synthetic progestogens, such as 6.beta.,7.beta.:15.beta.,16.beta.-Dimethylene-3-oxo-17.alpha.-pregn-4-ene- -21,17-carbolactone, as well as pharmaceutical compositions comprising the same. Also described are methods of use.
Inventor(s):	Perrin; Philippe (Paris, FR), Velada; Jose Luis (Amersfoort, NL), Drouin; Dominique (Verrieres-le-Buisson, FR)
Assignee:	LABORATORIOS LEON FARMA SA (Leon, ES)
Application Number:	17/711,966
Patent Claims:	1. A pharmaceutical composition comprising: 6.beta.,7.beta.:15.beta.,16.beta.-Dimethylene-3-oxo-17.alpha.-pregn-4-ene- -21,17-carbolactone in the form of particles that have a surface area ranging from about 2000 cm.sup.2/g to about 8500 cm.sup.2/g, wherein the 6.beta.,7.beta.:15.beta.,16.beta.-Dimethylene-3-oxo-17.alpha.-pregn-4-ene- -21,17-carbolactone is present in an amount ranging from 2 milligrams (mg) to 6 mg; and one or more pharmaceutically acceptable excipients, wherein the pharmaceutical composition does not comprise estrogen; and wherein the pharmaceutical composition is formulated such that, (1) when orally administered to a patient under fasting conditions, the pharmaceutical composition provides a pharmacokinetic profile for the 6.beta.,7.beta.:15.beta.,16.beta.-Dimethylene-3-oxo-17.alpha.-pregn-4-ene- -21,17-carbolactone comprising: (i) a mean T.sub.max ranging from 2.2 hours to 6 hours; and (ii) a mean C.sub.max of less than 30 ng/ml; and (no more than 50% of the 6.beta.,7.beta.:15.beta.,16.beta.-Dimethylene-3-oxo-17.alpha.-pregn-4-ene- -21,17-carbolactone initially present in the pharmaceutical composition is dissolved within 30 minutes if subjected to an in vitro dissolution test according to the USP XXIII Paddle Method. 2. The pharmaceutical composition of claim 1, wherein the one or more pharmaceutically acceptable excipients comprises a filler. 3. The pharmaceutical composition of claim 2, wherein the filler comprises lactose anhydrous, microcrystalline cellulose, starch, pregelatinized starch, modified starch, dibasic calcium phosphate dihydrate, calcium sulfate trihydrate, calcium sulfate dihydrate, calcium carbonate, lactose, dextrose, sucrose, mannitol, sorbitol, or a combination thereof. 4. The pharmaceutical composition of claim 1, wherein the one or more pharmaceutically acceptable excipients comprises a lubricant. 5. The pharmaceutical composition of claim 4, wherein the lubricant comprises magnesium stearate, calcium stearate, zinc stearate, talc, propylene glycol, PEG, stearic acid, vegetable oil, sodium benzoate, sodium lauryl sulfate, magnesium lauryl sulfate, mineral oil polyoxyethylene monostearate, or a combination thereof. 6. The pharmaceutical composition of claim 1, wherein the one or more pharmaceutically acceptable excipients comprises a binder. 7. The pharmaceutical composition of claim 6, wherein the binder comprises a starch, a gum, microcrystalline cellulose, hydroxypropyl cellulose, hydroxyethyl cellulose, hydroxypropylmethyl cellulose, polyvinyl pyrrolidone, or a combination thereof. 8. The pharmaceutical composition of claim 7, wherein the starch comprises potato starch, wheat starch, corn starch, or a combination thereof. 9. The pharmaceutical composition of claim 7, wherein the gum comprises gum tragacanth, acacia gum, gelatin, or a combination thereof. 10. The pharmaceutical composition of claim 1, wherein the one or more pharmaceutically acceptable excipients comprises a glidant. 11. The pharmaceutical composition of claim 10, wherein the glidant comprises silicon dioxide, magnesium trisilicate, powdered cellulose, starch, talc, tribasic calcium phosphate, or a combination thereof. 12. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition is formulated as a tablet or a capsule. 13. The pharmaceutical composition of claim 12, wherein the pharmaceutical composition further comprises a coating. 14. The pharmaceutical composition of claim 13, wherein the coating comprises hydroxypropylmethyl cellulose, hydroxypropyl cellulose, ethyl cellulose, or a combination thereof. 15. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition is formulated such that at least 55% of the 6.beta.,7.beta.:15.beta.,16.beta.-Dimethylene-3-oxo-17.alpha.-pregn-4-ene- -21,17-carbolactone initially present in the pharmaceutical composition is dissolved within 4 hours if subjected to the in vitro dissolution test according to the USP XXIII Paddle Method. 16. The pharmaceutical composition of claim 1, wherein the amount of the 6.beta.,7.beta.:15.beta.,16.beta.-Dimethylene-3-oxo-17.alpha.-pregn-4-ene- -21,17-carbolactone present ranges from 3.0 mg to 3.5 mg. 17. The pharmaceutical composition of claim 1, wherein the amount of the 6.beta.,7.beta.:15.beta.,16.beta.-Dimethylene-3-oxo-17.alpha.-pregn-4-ene- -21,17-carbolactone present is about 3.5 mg. 18. The pharmaceutical composition of claim 1, wherein the amount of the 6.beta.,7.beta.:15.beta.,16.beta.-Dimethylene-3-oxo-17.alpha.-pregn-4-ene- -21,17-carbolactone present is about 4.0 mg. 19. The pharmaceutical composition of claim 1, wherein the pharmacokinetic profile for the 6.beta.,7.beta.:15.beta.,16.beta.-Dimethylene-3-oxo-17.alpha.-pregn-4-ene- -21,17-carbolactone further comprises an AUC.sub.0.sub.h.sub.-t.sub.last of at least 350 ngh/ml. 20. The pharmaceutical composition of claim 1, wherein the pharmacokinetic profile for the 6.beta.,7.beta.:15.beta.,16.beta.-Dimethylene-3-oxo-17.alpha.-pregn-4-ene- -21,17-carbolactone further comprises an AUC.sub.0.sub.h.sub.-t.sub.last of at least 300 ngh/ml. 21. The pharmaceutical composition of claim 1, wherein the surface area ranges from 2000 cm.sup.2/g to 8500 cm.sup.2/g. 22. The pharmaceutical composition of claim 15, wherein the surface area ranges from 2000 cm.sup.2/g to 8500 cm.sup.2/g. 23. The pharmaceutical composition of claim 19, wherein the surface area ranges from 2000 cm.sup.2/g to 8500 cm.sup.2/g. 24. The pharmaceutical composition of claim 20, wherein the surface area ranges from 2000 cm.sup.2/g to 8500 cm.sup.2/g. 25. The pharmaceutical composition of claim 21, wherein the amount of the 6.beta.,7.beta.:15.beta.,16.beta.-Dimethylene-3-oxo-17.alpha.-pregn-4-ene- -21,17-carbolactone present ranges from 3.0 mg to 4.5 mg. 26. The pharmaceutical composition of claim 22, wherein the amount of the 6.beta.,7.beta.:15.beta.,16.beta.-Dimethylene-3-oxo-17.alpha.-pregn-4-ene- -21,17-carbolactone present ranges from 3.0 mg to 4.5 mg. 27. The pharmaceutical composition of claim 23, wherein the amount of the 6.beta.,7.beta.:15.beta.,16.beta.-Dimethylene-3-oxo-17.alpha.-pregn-4-ene- -21,17-carbolactone present ranges from 3.0 mg to 4.5 mg.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.